John Payne Biography and Net Worth

Director of ZIVO Bioscience


Mr. Payne was the founder of Compassion-First Pet Hospitals, and served as President and CEO from 2014 until 2020. Compassion-First Pet Hospitals, now NVA Compassion-First, is a family of specialty and emergency veterinary hospitals located throughout the United States that is dedicated to changing the veterinary landscape and elevating patient outcomes. Mr. Payne currently serves as Vice Chairman of National Veterinary Associates, with which Compassion-First Pet Hospitals combined. Prior to founding Compassion-First, Mr. Payne served as a member of the Global Leadership Team for Mars Pet Care. He also served as President and CEO of Banfield Pet Hospitals and as President and General Manager of Bayer Healthcare’s North American Animal Health Division.

Mr. Payne currently serves as Chairman of the Board for American Humane and as Vice Chairman of the Board of Regents at Ross University School of Medicine and School of Veterinary Medicine. He served on the Board of Directors of Nexvet, a bioscience company located in Dublin, Ireland, through the company’s acquisition by Zoetis in 2018.

How old is John Bernard Payne?

Mr. Payne is currently 76 years old. There are 1 older executives and no younger executives at ZIVO Bioscience. Learn More on John Bernard Payne's age.

How do I contact John Bernard Payne?

The corporate mailing address for Mr. Payne and other ZIVO Bioscience executives is 2804 ORCHARD LAKE ROAD SUITE 202, KEEGO HARBOR MI, 48320. ZIVO Bioscience can also be reached via phone at (248) 452-9866 and via email at [email protected]. Learn More on John Bernard Payne's contact information.

Has John Bernard Payne been buying or selling shares of ZIVO Bioscience?

John Bernard Payne has not been actively trading shares of ZIVO Bioscience during the last quarter. Most recently, on Thursday, January 27th, John Bernard Payne bought 7 shares of ZIVO Bioscience stock. The stock was acquired at an average cost of $15.00 per share, with a total value of $105.00. Learn More on John Bernard Payne's trading history.

Who are ZIVO Bioscience's active insiders?

ZIVO Bioscience's insider roster includes Christopher Maggiore (Director), Nola Masterson (Director), and John Payne (Director). Learn More on ZIVO Bioscience's active insiders.

John Bernard Payne Insider Trading History at ZIVO Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/27/2022Buy7$15.00$105.00View SEC Filing Icon  
1/25/2022Buy1,520$15.00$22,800.00View SEC Filing Icon  
See Full Table

John Bernard Payne Buying and Selling Activity at ZIVO Bioscience

This chart shows John Bernard Payne's buying and selling at ZIVO Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ZIVO Bioscience Company Overview

ZIVO Bioscience logo
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Read More

Today's Range

Now: $19.00
Low: $17.04
High: $19.00

50 Day Range

MA: $20.00
Low: $16.51
High: $22.00

2 Week Range

Now: $19.00
Low: $1.20
High: $22.15

Volume

2,619 shs

Average Volume

3,106 shs

Market Capitalization

$67.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.17